Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: "Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease." This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. Our podcast series does not constitute the practi ...